日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

Correction: Trajectory of the body weight after drug discontinuation in the treatment of anti-obesity medications

更正：抗肥胖药物治疗停药后体重的变化轨迹

期刊:BMC Medicine
影响因子:8.3
doi:10.1186/s12916-026-04817-9
Wu, Han; Yang, Wenjia; Guo, Tong; Cai, Xiaoling; Ji, Linong
肥胖
代谢
发表日期：2026
文献求助 收藏

The association between glucagon-like peptide-1 receptor agonists and reported musculoskeletal adverse events: a systematic review and meta-analysis of randomized controlled trials

胰高血糖素样肽-1受体激动剂与报告的肌肉骨骼不良事件之间的关联：随机对照试验的系统评价和荟萃分析

期刊:Therapeutic Advances in Musculoskeletal Disease
影响因子:4.1
doi:10.1177/1759720X261428147
Cao, Meng; Lin, Chu; Cai, Xiaoling; Lv, Fang; Yang, Wenjia; Ji, Linong
信号转导
发表日期：2026
文献求助 收藏

Characterizing echocardiographic abnormalities and their associated factors in patients with type 1 diabetes: a cross-sectional study

1型糖尿病患者超声心动图异常及其相关因素的特征分析：一项横断面研究

期刊:Cardiovascular Diabetology
影响因子:10.6
doi:10.1186/s12933-025-02926-y
Yang, Wenfeng; Lin, Chu; Cai, Xiaoling; Li, Zonglin; Lv, Fang; Yang, Wenjia; Liu, Geling; Yang, Xiaolin; Li, Sha; Ji, Linong
糖尿病
代谢
发表日期：2025
文献求助 收藏

Exon Sequencing of HNF1β in Chinese Patients with Early-Onset Diabetes.

中国早发性糖尿病患者HNF1β基因外显子测序

期刊:Diabetes & Metabolism Journal
影响因子:8.5
doi:10.4093/dmj.2024.0159
Gong Siqian, Lian Hong, Li Yating, Cai Xiaoling, Liu Wei, Luo Yingying, Li Meng, Zhang Si-Min, Zhang Rui, Zhou Lingli, Zhu Yu, Ren Qian, Zhang Xiuying, Chen Jing, Wu Jing, Zhou Xianghai, Wang Xirui, Han Xueyao, Ji Linong
代谢
糖尿病
发表日期：2025
文献求助 收藏

Trajectory of the body weight after drug discontinuation in the treatment of anti-obesity medications

抗肥胖药物治疗停药后体重变化轨迹

期刊:BMC Medicine
影响因子:8.3
doi:10.1186/s12916-025-04200-0
Wu, Han; Yang, Wenjia; Guo, Tong; Cai, Xiaoling; Ji, Linong
肥胖
代谢
发表日期：2025
文献求助 收藏

Comparison of glucose fluctuation between metformin combined with acarbose or sitagliptin in Chinese patients with type 2 diabetes: A multicenter, randomized, active-controlled, open-label, parallel design clinical trial

比较二甲双胍联合阿卡波糖或西格列汀治疗中国2型糖尿病患者血糖波动情况：一项多中心、随机、阳性对照、开放标签、平行设计的临床试验

期刊:Chinese Medical Journal
影响因子:7.3
doi:10.1097/CM9.0000000000003477
Cai, Xiaoling; Hu, Suiyuan; Lin, Chu; Wu, Jing; Wang, Junfen; Wang, Zhufeng; Zhang, Xiaomei; Wang, Xirui; Xu, Fengmei; Chen, Ling; Yang, Wenjia; Nie, Lin; Ji, Linong
糖尿病
代谢
发表日期：2025
文献求助 收藏

Anti-diabetic medications and cancer: links beyond glycemic and body weight control

抗糖尿病药物与癌症：血糖和体重控制之外的联系

期刊:Precision Clinical Medicine
影响因子:5
doi:10.1093/pcmedi/pbaf028
Cao, Meng; Lin, Chu; Cai, Xiaoling; Lv, Fang; Yang, Wenjia; Ji, Linong
糖尿病
肿瘤
肿瘤免疫
代谢
发表日期：2025
文献求助 收藏

PCSK9 Inhibitor and Potential Decreased Risk of Neoplasms, Especially in Females: A Meta-Analysis

PCSK9抑制剂与肿瘤风险降低的潜在关联，尤其是在女性中：一项荟萃分析

期刊:Pharmaceuticals
影响因子:4.8
doi:10.3390/ph18081095
Wei, Tingyang; Li, Zonglin; Lin, Chu; Yang, Yuteng; Tie, Changjie; Cai, Xiaoling; Lv, Fang; Yang, Wenjia; Ji, Linong
CSK
肿瘤
PCSK9
肿瘤免疫
发表日期：2025
文献求助 收藏

Morning spot urinary cortisol-to-creatinine ratio: a novel screening tool for assessing excess cortisol secretion

晨尿皮质醇/肌酐比值：一种评估皮质醇分泌过多的新型筛查工具

期刊:Frontiers in Endocrinology
影响因子:4.6
doi:10.3389/fendo.2025.1663619
Liu, Yingning; Zhang, Ping; Zhang, Simin; Gao, Ying; Mu, Yiqing; Lian, Hong; Ren, Qian; Cai, Xiaoling; Zhou, Xianghai; Han, Xueyao; Ji, Linong; Zou, Xiantong
发表日期：2025
文献求助 收藏

Clinical characteristics and unique presentations of immune checkpoint inhibitor induced type 1 diabetes in Chinese patients from a single institution

单一机构中中国患者免疫检查点抑制剂诱发的1型糖尿病的临床特征和独特表现

期刊:Scientific Reports
影响因子:3.9
doi:10.1038/s41598-025-89668-9
Liu, Wei; Li, Chunmei; Fang, Yayu; Cai, Xiaoling; Zhu, Yu; Ren, Qian; Zhang, Rui; Zhang, Mingxia; Gao, Ying; Han, Xueyao; Li, Juan; Yin, Sai; Huo, Yongran; Ji, Linong
代谢
糖尿病
免疫/内分泌
发表日期：2025
文献求助 收藏